Sequential immunophenotypes of bone marrow (BM) and peripheral blood (PBL) lymphoid cells from 15 B-lineage acute lymphoblastic leukemia (ALL) patients who underwent autologous bone marrow transplantation (BMT) during complete remission were determined by dual-color immunofluorescence and multiparameter flow cytometry. Autografts were depleted of CD19+ B-cell precursors by an immunochemopurging protocol that combines B43-PAP. a potent anti-CD19 immunotoxin, and the cyclophosphamide congener 4-hydroperoxycyclophosphamide (4-HC). A marked interpatient variation was observed in the appearance and expansion of B-cell precursors repopulating the posttransplant marrow. The expression of CDIO and CD19 antigens during early B-cell ontogeny post-BMT preceded the expression of CD20, CD21, CD22, CD40, and slgM. The surface antigen profiles of the emerging B-cell precursors were similar t o those of fetal liver or fetal bone marrow B-cell precursors. Our comparisons of BM and PBL samples from patients in the early post-BMT period demonstrated that (1) PBL initially contains fewer B-lineage cells than does BM, and (2) The hypothetical models of human B-cell ontogeny and the developmental hierarchy of antigen expression are largely based on studies using leukemic B-cell precursors from B-lineage acute lymphoblastic leukemia (ALL) patients, which are thought to originate from developmental lesions and maturational arrest in normal B-cell precursor clones during early phases of More recently, sophisticated multiparameter flow cytometry and cell sorting techniques, as well as in vitro clonal assays that permit B-lineage differentiation of human fetal B-cell precursors, have been used to directly analyze the developmental hierarchy in human B-cell ~n t o g e n y ? ,~J l -~~ These studies using normal B-cell precursor populations challenged aspects of the hypothetical models based on leukemic B-cell precursor^.^,^,^^,^^ Notably, significant immunophenotypic differences between B-cell precursors in fetal liver or fetal bone marrow (BM) and B-cell precursors in adult BM were o b~e r v e d~.~J~J~ that may reflect qualitative, as well as quantitative, differences in growth-stimulating or differentiation-inducing signals of different microenvironments or the coexistence of multiple B-cell precursor differentiation pathways. ' The primary purpose of this study was to examine the developmental hierarchy of antigen expression and to determine the composite immunophenotype of the emerg-BM or PBL lymphoid cells showed an increase in the percentages of CDlO+CD22-undifferentiated lymphocyte precursors, as well as CD19+slgM-B-cell precursors (pre-pre-B), consistent with a time-dependent expansion of these B-cell precursor populations post-BMT. Importantly, the percentages of CD10+CD22+ and CD19+slgM+ B-cell precursor (pre-B) populations also increased between 30 days and 1 year post-BMT, confirming the ability of emerging immature B-cell precursors t o differentiate along the B-precursor pathway. The acquisition and expression of B-lineage differentiation antigens at different stages of the post-BMT B-cell ontogeny support the notion that the expression of these antigens is developmentally programmed. Similar t o patients in previous autologous BMT studies, recipients of B-cell precursordepleted autografts had normal or nearly normal serum immunoglobulin levels, suggesting that the maturing B-cell/ plasma cell populations can produce and secrete immunoglobulins. The development of a functional CD19+ B-lineage lymphoid compartment in recipients of autografts which were depleted of CD19+ B-cell precursors corroborates the previously postulated existence of CD19-B-lineage lymphoid progenitor cells. 0 1992 by The American Society of Hematology.
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ing B-cell precursor populations during the earliest stages of B-cell ontogeny after autologous bone marrow transplantation (BMT). BM and peripheral blood (PBL) samples from 15 patients undergoing autologous BMT were analyzed at multiple time points post-BMT by quantitative 3370 UCKUN ET AL multiparameter flow cytometry. Autografts were purged of CD19+ normal and leukemic B-cell precursors by B43-PAP, an anti-CD19 pan-B-cell i m m u n~t o x i n ,~~-*~ in combination with low-dose 4-hydroperoxycyclophosphamide . Serum immunoglobulin levels were determined to assess the in vivo function of recovering B-cell populations. Fetal liver and fetal BM B-cell precursors, as well as pediatric and adult BM B-cell precursors, were also examined for their immunophenotypic differences and similarities to B-cell precursors repopulating the posttransplant BM. Most importantly, we analyzed the earliest stages of human B-cell ontogeny originating from CD19-B-lineage lymphoid progenitor cells, since CD19+ B-cell precursors were eliminated from the autografts by a combination of B43-PAP immunotoxin and 4-HC.
MATERIALS AND METHODS
Human fetal liver and fetal BM samples. Human fetal liver and fetal BM specimens were obtained from prostaglandin-induced human abortuses of 16 to 21 weeks' gestational age. Subsequently, cell suspensions were prepared and mononuclear cells were isolated by centrifugation on Ficoll-Hypaque gradients, as previously r e p~r t e d .~ All fetal tissue specimens were used following the guidelines of the University of Minnesota Committee on the Use of Human Subjects in Research for secondary use of pathologic or surgical tissue.
Between September 20, 1989 and May 28,1991,15 patients with B-lineage ALL in complete remission were enrolled in a clinical study of autologous BMT using autografts that were purged exvivo using a potent anti-CD19 immunotoxin, B43-PAP, in combination with 4-HC, as previously d e~c r i b e d .~~. '~ The study protocol was approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota, and written informed consent was obtained from all patients before entering the study according to Department of Health and Human Services (DHHS) guidelines.
All patients were conditioned with hyperfractionated total body irradiation (TBI; 1,375 cGy total dose delivered in 11 125-cGy fractions on days -7, -6, -5, and -4) followed by 60 mg/kg/d cyclophosphamide on days -3 and -2, which was administered as a 1-hour intravenous (IV) infusion on each day.'* After 1 day of rest (day -l), autografts were thawed and administered on day 0. Supportive care during the hospital stay was provided as previously described.19 BM and/or PBL samples were obtained at 30 days, 100 days, and when available, 1 year post-BMT. At each time point, the remission status of BM was confirmed by morphological analysis combined with TdT staining. Controls included normal BM specimens from four healthy volunteer donors and PBL samples from (1) three remission B-lineage ALL patients who underwent allogeneic BMT following conditioning with fractionated TBI plus cyclophosphamide; (2) one remission acute nonlymphocytic leukemia (ANLL) patient who underwent autologous BMT with a 4-HC purged autograft following conditioning with busulfan plus cyclophosphamide; (3) The immunoglobulin levels in the collected serum samples were quantitatively determined by rate nephelometry using IgA, IgG, and IgM reagents in conjunction with Array Protein System, a fully automated protein analyzer from Beckman (Fullerton, CA). The IgE levels were determined by a fluorometric enzyme immunoassay using the IgE fluorometric enzyme immunoassay kit from Baxter (Miami, FL). IgG subclasses were quantitated by radial immunodiffusion using single-dilution RID kits from Binding Site (Birmingham, UK). All assays were performed by the University of Minnesota Hospital Protein Chemistry Laboratory.
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r B-cell precursor populations in fetal hematopoietic tissues and postnatal BM. We first performed quantitative multiparameter flow cytometric analyses on three fetal livers and two fetal BM samples to elucidate the surface antigen profiles of normal fetal B-cell precursor populations ( Table  1 ). The pairwise expression of B-lineage differentiation antigens on fetal lymphoid cells is illustrated in the FACScorrelated two-parameter displays shown in Fig 1. As shown in Table 1 Fig 1) . As shown in Table 1 and Fig 1, 22 .5% f 1.6% of fetal lymphoid cells coexpressed CDlO and surface IgM, in accordance with previous reports that immature B-cell precursors express surface p associated with an immunoglobulin A-chain-like pseuddight-chain protein complex. 21, 22 In comparison to CD10, CD19, and sIgM, CD20, CD21, CD22, CD24, and sIgD were expressed on a significantly smaller proportion of fetal lymphoid cells. Thus, many of the B-lineagecommitted CDlO+CD19+ B-cell precursors in fetal hematopoietic tissues were at an immature developmental stage and had not yet acquired other B-lineage differentiation antigens such as CD20, CD21, CD22, CD24, or sIgD. The composite immunophenotypes of the two dominant CD10+ lymphocyte precursor populations were CDlO+CD19-CD20-CD21-CD22 -sIgD-sIgM+/-(undifferentiated lymphocyte precursors) and CDlO+CD19+CD20-CD21-CD22-sIgD-sIgM+/-(stage I1 B-cell precursors). We have previously reported that the vast majority of CDlO+CD19-undifferentiated lymphoid cells in fetal hematopoietic tissues represent immature stage 0/1 B-cell precursors capable of differentiating into CDlO+CD19+ stage I1 B-cell precursors. 5 We next performed multiparameter flow cytometric analyses on two fetal BM samples to correlate the expression of B-lineage lymphoid differentiation antigens CD10, CD20, CD21, CD22, CD24, sIgD, and sIgM, and to compare their sequence of acquisition on CD19+ fetal lymphoid cells. As shown in Table 2 , the percentage of CD19+ cells was significantly greater than the percentages of cells expressing CD20, CD21, CD22, CD24, sIgD, or sIgM. Of CD19+ cells, greater than 90% were CD10+ and 29% to 38% were sIgM+. The majority of CDlO+CD19+sIgM+ cells were
C D~O -C D~~-C D~~-C D~~-S I~D -.
These results provide corroborative evidence that (1) the expression of CDlO and CD19 precedes the acquisition of CD20, CD21, CD22, CD24, sIgM, and sIgD, and (2) surface p is acquired earlier than CD20, CD21, CD22, CD24, and sIgD. In summary, the composite immunophenotype of the majority of CD19+ fetal B-cell precursor populations was CDlO+CD19+ CD20-CD21-CD22 -CD24-sIgD-sIgM+/-. B-cell precursors repopulating BM and circulating in PBL after autologous BMT with B-cell precursordepleted autograjls. To study the developmental hierarchy of expression for B-lineage lymphoid differentiation antigens during early B-cell ontogeny after autologous BMT, we performed sequential multiparameter immunofluorescence analyses on lymphoid cells from BM and/or PBL specimens of 15 B-lineage ALL remission patients who received B-cell precursor-depleted autografts. All 15 patients engrafted, as defined by a white blood cell (WBC) count greater than l,OOO/pL for 3 consecutive days, at a median of 23 days (range, 13 to 62 days; mean 2 SE, 29 4 days). Engraftment was stable in all 15 patients and no patient required Gestational age (wk) CD19/CD10 expression CD19+ (% of total) CDlO+ (%of total) infusion of hematopoietic cytokines recombinant granulocyte colony-stimulating factor (rG-CSF), recombinant granulocyte-macrophage CSF (rGM-CSF), or unpurged BM cells. At each time point, the BM remission status was confirmed by morphologic examination of BM biopsy and aspirate specimens, as well as nuclear TdT staining. As shown in Table 3 , there was a marked interpatient variation in the emergence and expansion of B-cell precursor populations regenerating post-BMT BM. Overall, the immunophenotypic features of these B-cell precursors were similar to those found in fetal liver and BM samples. The mean percentages of CD10+ cells in the day 30 BM samples were slightly higher than the mean percentages of CD19+ (P = .15) or CD20+ (P = than the mean percentages of CD21+, CD22+, CD40+, or sIgM+ cells (P < .05) ( Table 3 ). The mean percentages of CD19+ cells in the day 30 and especially day 100 BM samples were greater than the percentages of CD20+, CD21+, CD22+, CD24+, CD40+, or sIgM+ cells. Thus in many patients, the expression of CDlO and CD19 antigens during early B-cell ontogeny post-BMT appeared to precede the expression of other antigens, consistent with previous reports regarding the developmental hierarchy of antigen expression in human B-cell ontogeny,'-' and with our aforementioned results on fetal B-cell precursors. The comparison of the surface antigen profiles of day 30 versus day 100 or year 1 BM lymphoid cells showed an increase in the percentages of CD10+CD22-undifferentiated lymphocyte precursors, as well as CD19+sIgM-stage I1 cell precursors (pre-pre-B), consistent with a time-dependent expansion of these cell populations post-BMT (Table 3 , Figs 2A and B, Fig 3) . Importantly, the percentages of CDlO+CD22+ and CD19+sIgM+ stage 111 B-cell precursor (pre-B) populations also increased between 30 days and 1 year post-BMT, confirming the ability of emerging immature B-cell precursor populations to differentiate along the B-precursor pathway. While the level of expression of B-lineage differentiation antigens CD10, CD19, CD20, CD21, CD22, CD40, and IgM on regenerating BM lymphoid cells analyzed on day 30 post-BMT was lower than their level of expression on normal BM lymphoid cells, the percent positivity of BM lymphoid cells for each of these antigens reached near-to-normal values on day 100 post-BMT (Table 3) . (Table 4) . Notably, distinct populations of CDlO'CD22-undifferentiated lymphocyte precursors, as well as CD19'sIgM-stage I1 B-cell precursors, were discernible in day 30 PBL. Their percentage and, in particular, the percentage of their more mature progeny, as measured by the percentages of CD19+sIgM+. CDIO+CD22+ cells or the total percentages of CD20+, CD21+, CD22+, CD40+, or sIgM+ cells, continued to increase in a time-dependent fashion (Table 4, Fig 4) . By day 100 post-BMT. the percentages of B-lineage lymphoid cells with mature immunophenotypes (CDlO+CD22+, CD19+sIgM+, CD20'. CD22+, CD40+) were higher in PBL than they were in BM. The emergence of B-cell precursor populations in the early posttransplant period did not appear to be slower among recipients of B-cell precursordepleted autografts than among control patient groups shown in Table 4 .
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Serum immunoglobulin levels ajer autologous BMT with B-cell precursor4epleted a u t o p j s . The post-BMT serum immunoglobulin levels were monitored in 10 of 15 patients. Four of these 10 patients (UPN 1174, UPN 1201, UPN 1202, UPN 1284) were on supportive IV immunoglobulin therapy and their serum immunoglobulin levels were within normal limits ( Table 5 ). In three (UPN 1227, UPN 1249, UPN 131 1) of the remaining six patients, the day 100 sIgG levels were slightly below normal. In two (UPN 1161, UPN   1326 ) of the six patients who did not receive IV immunoglobulin therapy, the day 100 serum levels for total IgG and IgG subclasses were within normal limits. Similarly, in one patient (UPN 1202) who was on IV immunoglobulin therapy for 6 months, the 1-year serum levels for total IgG and IgG subclasses were within the normal range. Among the six patients who did not receive any IV immunoglobulin therapy, five had normal IgA levels and one had below normal IgA levels. All six patients had detectable IgE levels and either normal or nearly normal IgM levels ( Table 5) . Taken together, these results demonstrate that patients receiving B-cell precursor-depleted autografts did not develop a profound humoral immunodeficiency. Table 3 .
DISCUSSION
The surface antigen profiles of circulating sIg+ B-cells have been examincd in a limited number of published studies using a small number of Btell-reactive MoAbs.L'.2X Most of the work involved recipients of allogeneic BM, and the collected data represent single time point detcrminations on PBL samples.z'-2H As reviewed by L u d 3 and Zander and Aksamit,29 the repopulation of B cells to normal numbers in the PBL occurs within 2 to 3 months after BMT. Small et al reported the surface antigen profiles of circulating lymphocytes from 88 patients after allogeneic (n = 29), T-cell-depleted allogeneic (n = 44), or autologous (n = 15) BMT.Z5 B cells in the early posttransplant period shared a number of phenotypic and functional similarities with B cells found in cord blood, supporting the hypothesis that Bcell differentiation post-BMT represents a recapitulation of normal B-cell ~n t o g e n y .~~. ?~ While these studies enhanced our understanding of B-cell immune reconstitution after BMT, they did not explore the earliest events of human B-ccll ontogeny in regencrating BM. To our knowledge, no previous study has ( I ) cxamincd the sequential and correlated acquisition of the B-lineage differentiation antigens CDlO, CD19, CD20, CD21, CD22, CD24, CD40, and IgM on BM B-cell precursor populations post-BMT; (2) described immunophenotypic differences between BM B-cell precursors and circulating PBL B-cell precursors post-BMT; or (3) directly compared the surface antigen profiles of fetal liver, fetal BM, or postnatal BM B-ccll precursors to those of post-BMT B-cell precursors.
The present study describes the surface antigen profiles of emerging B-cell precursor populations after autologous BMT. We were able to examine the dcvelopmental hicrarchy of antigen expression during the earliest stages of Our comparative analysis of BM and PBL samples obtained from patients at specific time points in the early post-BMT period demonstrated that (1) PBL initially contains fewer B-lineage cells than does BM, and (2) circulating B-lineage lymphoid cells have a more mature immunophenotype than do BM B-lineage lymphoid cells. From these differences we infer that BM provides a uniquely suitable microenvironment for the self-renewal and expansion of immature B-cell precursor populations after BMT.
Numerous BMT centers have provided unambiguous evidence for functional deficits in repopulating B-cell populations after allogeneic BMT.3143 A humoral immunodeficiency occurs immediately after allogeneic BMT and involves immunoglobulin isotypes IgG, IgA, and IgM?1-36 Velardi et al" and Aucouturier et a14' reported selective and sustained IgG2 and IgG4 subclass deficiencies in the serum of virtually all allogeneic BMT recipients. Although the total serum IgG and IgM levels return to normal within 6 months, the serum IgA, IgG2, and IgG4 levels remain low, and the in vitro and in vivo B-cell functions remain impaired for at least 1 year after allogeneic BMT.34,38,4447
As reviewed by L~m , 2~ allogeneic and syngeneic marrow recipients have severely depressed antibody responses to immunizations during the first 6 months post-BMT. In contrast to the humoral immunodeficiency of allogeneic BMT recipients, serum levels of IgG and IgM in autologous BMT patients are at the lower end of the normal range.38,48,49 Recently, Kiesel et a1 studied the proliferative and functional responses of circulating B cells after autologous BMT or peripheral stem cell tran~plantation.~~ In vitro IgG/IgM production by circulating B cells was normal in 19 of 22 patients and the patients had normal serum IgG levels, but the serum IgA levels were low. Thus, the ability of developing B cells to secrete IgG appears to be less compromised in autologous BMT recipients as compared with allogeneic BMT recipients. Similar to previous autologous BMT studies, our study showed nearly normal sIgA, sIgG, and sIgM levels in the majority of patients who did not receive IgG replacement therapy as part of their peritransplant supportive care. Selective IgG2 or IgG4 deficiencies were not observed. The source of serum immunoglobulins are likely the mature B-cell progeny of the reinfused B-lineage progenitor cells. However, we cannot completely exclude other possibilities, including (1) persistent host antibodies of the recipients, (2) passively acquired antibody via blood Table 4. product support, or (3) prcscncc of radiation-resistant noncirculating mature B-ccll populations in lymph nodes and/or splccn (not dctectablc by immunophcnotypic analyses of PBL samples), which rctain thcir ability to secrete IgG.
In summary, wc cxamincd thc dcvclopmcntal hierarchy during thc carlicst stages of human B-ccll ontogcny in a unique autologous BMT model system. Our study provides a paradigm for thc analysis of thc tcmporal association of thc acquisition of B-lineage differentiation antigcns on emerging B-cell prccursor populations within different stagcs of post-BMT ontogcny. This rcport describes the dcvclopmcnt of a functional CD19' B-lineage lymphoid compartmcnt originating from CD19-immature B-ccll prccursors as thc first formal cvidcncc for thc recently postulatcd cxistcncc of CD19-B-lincagc lymphoid progcnitor ccll populations.s A basis is providcd for future analyses of thc immunobiologic fcaturcs of human B-ccll precursor populations in modcls such as thc SCID-hu mouse. The rcsult should bc a morc cohcrcnt picturc of the early stagcs of B-cell ontogeny. Bccausc of thc relatively small number of post-BMT PBL and BM samplcs tested, thc conclusions of this study will nccd furthcr validation in a largcr paticnt scrics. 
